การฉีดวัคซีนป้องกันไวรัสตับอักเสบบีในระหว่างตั้งครรภ์เพื่อป้องกันการติดเชื้อในทารก
Referencias
References to studies excluded from this review
Gupta I, Ratho RK. Immunogenicity and safety of two schedules of Hepatitis B vaccination during pregnancy. Journal of Obstetrics and Gynaecology Research 2003;29(2):84‐6.
Li XM, Yang YB, Hou HY, Shi ZJ, Shen HM, Teng BQ, et al. Interruption of HBV intrauterine transmission: a clinical study. World Journal of Gastroenterology 2003;9(7):1501‐3.
Li XM, Shi MF, Yang YB, Shi ZJ, Hou HY, Shen HM, et al. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World Journal of Gastroenterology 2004;10(21):3215‐7.
Patwardhan A, Jamjute P, Peter G. Foetal immunoprophylaxis with hepatitis‐B vaccine could be a cost effective approach towards eradication in the high‐risk population. Journal of Pediatric Gastroenterology and Nutrition 2005;40(5):678.
Wang FY, Lin P, Zhang HZ. [A randomized controlled trial on effect of hepatitis B immune globulin in preventing hepatitis B virus transmission from mothers to infants]. [Chinese]. Zhonghua Erke Zazhi 2008;46(1):61‐3.
Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li M, et al. Efficacy and safety of lamivudine in late pregnancy for the prevention of mother‐child transmission of hepatitis B; a multicentre, randomised, double‐blind, placebo‐controlled study. Hepatology 2004;40(4 Suppl 1):272A‐273A.
Xu Q, Xiao L, Lu XB, Zhang YX, Cai X. A randomized controlled clinical trial: interruption of intrauterine transmission of hepatitis B virus infection with HBIG. World Journal of Gastroenterology 2006;12(21):3434‐7.
Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double‐blind, placebo‐controlled study. Journal of Viral Hepatitis 2009;16(2):94‐103.
Yu F, Xin QX, Li DR. Clinical observation of blocking HBV intrauterine infection by injection of hepatitis B immunoglobulin before laboring. Clinical Medicine of China 2003;19(11):1049‐50.
Yuan J, Lin J, Xu A, Li H, Hu B, Chen J, et al. Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single‐centre randomized study. Journal of Viral Hepatitis 2006;13(9):597‐604.
Yue Y, Yang X, Zhang S. Prevention of intrauterine infection by hepatitis B virus with hepatitis B immune globulin: efficacy and mechanism. Chinese Medical Journal 1999;112(1):37‐9.
Zhu Q, Lu Q, Gu X, Xu H, Duan S. A preliminary study on interruption of HBV transmission in uterus. Chinese Medical Journal 1997;110:145‐7.
Zhu Q, Yu G, Yu H, Lu Q, Gu X, Dong Z, et al. A randomized control trial on interruption of HBV transmission in uterus. Chinese Medical Journal 2003;116(5):685‐7.
Additional references
Andre FE. Summary of safety and efficacy data on a yeast derived hepatitis B vaccine. American Journal of Medicine 1989;87(Suppl 3A):14S‐20S.
Anonymous. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). Morbidity and Mortality Weekly Report. Recommendations and Reports1991; Vol. 40, issue RR‐13:1‐25.
Assad S, Francis A. Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 1999;18(1‐2):57‐67.
Beasley RP, Stevens CE, Shiao IS, Meng HC. Evidence against breastfeeding as a mechanism for vertical transmission of hepatitis B. Lancet 1975;2(7938):740‐1.
Chang MH. Hepatocellular carcinoma in children. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1998;39(6):366‐70.
De Lalla F, Rinaldi E, Santoro D, Pravettoni G. Immune response to hepatitis B vaccine given at different injection sites and by different routes: a controlled randomized study. European Journal of Epidemiology 1988;4(2):256‐8.
Ghendon Y. Perinatal transmission of hepatitis B virus in high‐incidence countries. Journal of Virological Methods 1987;17(1‐2):69‐79.
Gitlin N. Hepatitis B: diagnosis, prevention, and treatment. Clinical Chemistry 1997;43(8 Pt 2):1500‐6.
GRADE [Computer program]. Brozek J, Oxman A, Schünemann H. Version 3.6 for Windows2008.
Greenberg DP. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunization studies. Pediatric Infectious Disease Journal 1993;12(5):438‐45.
Grosheide PM, Schalm SW, Van Os HC, Fetter WP, Heijtink RA. Immune response to hepatitis B vaccine in pregnant women receiving post‐exposure prophylaxis. European Journal of Obstetrics & Gynecology and Reproductive Biology 1993;50(1):53‐8.
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hollinger FB, Liang TJ. Hepatitis B virus. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA editor(s). Fields Virology. 4th Edition. Philadelphia: Lippincott Williams & Wilkins, 2001:2971‐3036.
Hsieh CC, Tzonou A, Zavitsanos X, Kaklamani E, Lan SJ, Trichopoulos D. Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk. A birth order study. American Journal of Epidemiology 1992;136(9):1115‐21.
Ingardia CJ, Kelley L, Steinfeld JD, Wax JR. Hepatitis B vaccination in pregnancy: factors influencing efficacy. Obstetrics & Gynecology 1999;93(6):983‐6.
Jackson Y, Chappuis F, Mezger N, Kanappa K, Loutan L. High immunogenicity of delayed third dose of hepatitis B vaccine in travellers. Vaccine 2007;25(17):3482‐4.
Krugman S, Holley HP, Davidson M, Simberkoff MS, Matsaniotis N. Immunogenic effect of inactivated hepatitis B vaccine: comparison of 20 microgram and 40 microgram doses. Journal of Medical Virology 1981;8(2):119‐21.
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis 2004;11(2):97‐107.
Levy M, Koren G. Hepatitis B vaccine in pregnancy: maternal and fetal safety. American Journal of Perinatology 1991;8:227‐32.
Mahoney FJ, Woodruff BA, Erben JJ, Coleman PJ, Reid EC, Schatz GC, et al. Effect of a hepatitis B vaccination program on the prevalence of hepatitis B virus infection. Journal of Infectious Diseases 1993;167(1):203‐7.
Mahoney FJ, Kane M. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA editor(s). Vaccines. 3rd Edition. Philadelphia: W.B. Saunders Company, 1999:158‐82.
McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B‐related sequelae. Prospective study in 1400 hepatitis B surface antigen‐positive Alaska Native carriers. Archives of Internal Medicine 1990;150(5):1051‐4.
Ngui SL, Andrews NJ, Underhill GS, Heptonstall J, Teo CG. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clinical Infectious Diseases 1998;27(1):100‐6.
Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. International Journal of Cancer 2001;94(2):153‐6.
Reddy PA, Gupta I, Ganguly NK. Hepatitis‐B vaccination in pregnancy: safety and immunogenic response in mothers and antibody transfer to neonates. Asia‐Oceania Journal of Obstetrics and Gynaecology 1994;20(4):361‐5.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Safary A, Beck J. Vaccination against hepatitis B: current challenges for Asian countries and future directions. Journal of Gastroenterology and Hepatology 2000;15(4):396‐401.
Schunemann HJ. GRADE: from grading the evidence to developing recommendations. A description of the system and a proposal regarding the transferability of the results of clinical research to clinical practice [GRADE: Von der Evidenz zur Empfehlung. Beschreibung des Systems und Losungsbeitrag zur Ubertragbarkeit von Studienergebnissen]. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen 2009;103(6):391‐400.
Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiologic Reviews 2006;28:112‐25.
Stevens CE, Toy PT, Tong MJ, Taylor PE, Vyas GN, Nair PV, et al. Perinatal hepatitis B virus transmission in the United States. Prevention by passive‐active immunization. JAMA 1985;253(12):1740‐5.
Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink‐Brongers EE, Yeung CY, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis‐B vaccine and hepatitis‐B immunoglobulin. Double‐blind randomised placebo controlled study. Lancet 1984;1(8383):921‐6.
References to other published versions of this review
Sangkomkamhang US, Lumbiganon P, Laopaiboon M. Hepatitis B vaccination during pregnancy for preventing infant infection. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD007879.pub2]
Characteristics of studies
Characteristics of excluded studies [ordered by study ID]
| Study | Reason for exclusion |
| Study on immunogenicity and safety of HBV vaccine, comparisons of 2 doses HBV vaccine versus 3 doses in HBsAg negative pregnant women. | |
| Study on 3 comparisons of HBIG versus lamivudine versus no treatment in HBsAg positive pregnant women for prevention of intrauterine infection of HBV. | |
| Study on HBIG versus placebo in HBsAg positive pregnant women for prevention of intrauterine infection of HBV. | |
| Study on HBV vaccine in both non‐pregnant and pregnant women for prevention of vertical transmission. Abstract only. | |
| Study on HBIG in HBsAg and HBeAg positive pregnant women for prevention of mother to infant HBV transmission. | |
| Study on lamivudine versus placebo in late pregnancy for mothers with high viremia, in addition to HBV vaccination plus HBIG for the infants for prevention of mother‐to‐child transmission of HBV. | |
| Study on HBIG versus placebo in HBeAg and HBsAg positive pregnant women for prevention of intrauterine infection of HBV. | |
| Study on lamivudine in highly viremic and late pregnancy for prevention of perinatal transmission of HBV infection. | |
| Study on HBIG in HBsAg positive pregnant women for prevention of intrauterine infection. This was an observational study. | |
| Study on 3 doses of HBIG in seropositive for hepatitis B e antigen (HBeAg) pregnant women versus no treatment for prevention of mother‐to‐child transmission of HBV. | |
| Study on HBIG in seropositive for hepatitis B surface (HBsAg) antigen pregnant women versus no treatment for prevention of mother‐to‐child transmission of HBV. | |
| Study on HBIG in HBV carriers pregnant women versus no treatment for prevention of mother‐to‐child transmission of HBV. | |
| Study on 3 doses of HBIG in HBsAg carrier pregnant women versus no treatment for prevention of intrauterine transmission of HBV. |
HBeAG: hepatitis B e antigen
HBIG: hepatitis B immunoglobulin
HBsAg: hepatitis B surface antigen
HBV: hepatitis B virus
